Eflornithine

證據等級: L5

預測適應症: 2 個

Eflornithine: From African Trypanosomiasis/Hirsutism to Esotropia (Low-Confidence Prediction)

One-Sentence Summary

Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor known clinically for treating African trypanosomiasis and, topically, facial hirsutism. TxGNN predicts a possible new indication for Esotropia, but this is supported by 0 clinical trials and 0 publications, and the model's own rationale flags no plausible pharmacological link — this is a model-only signal, not evidence-backed.

Quick Overview

Item	Content
Original Indication	Not on record in this dataset (no Taiwan license/formal indication text available); known clinical uses per available evidence: African trypanosomiasis, topical treatment of facial hirsutism
Predicted New Indication	Esotropia
TxGNN Prediction Score	99.85%
Evidence Level	L5
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action (MOA) data is not available in the formal original_moa field for this candidate (flagged as a Blocking data gap, DG001/DG002). Based on the supplementary evidence attached to this prediction, eflornithine is understood to irreversibly inhibit ornithine decarboxylase (ODC), blocking polyamine synthesis — a mechanism underlying its established use in African trypanosomiasis (antiparasitic) and topical suppression of facial hair growth (antiproliferative effect on hair follicles).

Esotropia is a disorder of extraocular muscle tone/neuromuscular control, not a proliferative, parasitic, or polyamine-dependent condition. The model's own repurposing rationale explicitly states there is no known physiological or pharmacological mechanism connecting ODC inhibition/polyamine blockade to esotropia, and assesses this prediction as most likely an artifact ("noise") of the TxGNN embedding space rather than a biologically grounded signal.

A secondary candidate, neurotrophic keratopathy (rank 2, score 99.38%), was also evaluated but shows a similarly unsupported — and potentially mechanistically unfavorable — link: ODC inhibition would be expected to reduce polyamine-driven corneal epithelial regeneration rather than improve it. Neither candidate has any corroborating trial or literature evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Eflornithine is not currently marketed in Taiwan; no license records are available (total_licenses = 0).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data are not available in this evidence pack — resolving this is a Blocking gap, DG001, required before any S1 safety evaluation can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests solely on a TxGNN model score (L5) with no clinical trials, no literature, and no plausible mechanistic pathway identified by the model's own rationale — in fact, the mechanism plausibly points the opposite direction for the secondary candidate. Combined with a Blocking gap on TFDA/label safety data (DG001) and a missing formal MOA (DG002), this candidate cannot advance past S0.

To proceed, the following is needed:

Confirmed original MOA and approved indication(s) from DrugBank/regulatory source (resolve DG002)
TFDA (or equivalent) label warnings/contraindications (resolve DG001, Blocking — required before any S1 safety review)
Independent pharmacological plausibility review for esotropia given the absence of a mechanistic rationale
Ongoing literature/trial surveillance in case new evidence emerges, given the current absence of any supporting study
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.